Wenhao Yang, Xiangtu Kong, Hui Yu, Xiaosu Feng, Haiwen Ni
{"title":"卡非佐米治疗复发和难治性多发性骨髓瘤的比较分析：一项荟萃分析。","authors":"Wenhao Yang, Xiangtu Kong, Hui Yu, Xiaosu Feng, Haiwen Ni","doi":"10.1177/20406207251359650","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>While carfilzomib has shown effectiveness in treating relapsed or refractory multiple myeloma (RRMM), the best frequency of dosing is still debated. This meta-analysis aims to investigate the differences in safety and effectiveness between once-weekly and twice-weekly carfilzomib treatment schedules for patients with RRMM.</p><p><strong>Methods: </strong>A thorough search of five databases was performed. We calculated pooled relative risks (RRs), hazard ratios (HRs), and 95% confidence intervals (95% CIs), and conducted heterogeneity and sensitivity analyses using StateMP 18 software.</p><p><strong>Results: </strong>Five studies met the inclusion criteria. Analysis indicated that once-weekly carfilzomib significantly enhanced progression-free survival (HR: 0.80, 95% CI: 0.69-0.94, <i>p</i> = 0.007). However, no statistical difference was observed in the pooled RRs for overall response rate (RR: 1.13, 95% CI: 0.94-1.38, <i>p</i> = 0.198) and complete response or better (RR: 2.08, 95% CI: 0.65-6.65, <i>p</i> = 0.217). The once-weekly regimen was notably associated with a reduction in adverse events (RR: 0.98, 95% CI: 0.96-1.00, <i>p</i> = 0.047) relative to the twice-weekly regimen.</p><p><strong>Conclusion: </strong>The results propose once-weekly carfilzomib as a viable alternative treatment option for RRMM.</p>","PeriodicalId":23048,"journal":{"name":"Therapeutic Advances in Hematology","volume":"16 ","pages":"20406207251359650"},"PeriodicalIF":3.1000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501438/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparative analysis of once-weekly versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma: a meta-analysis.\",\"authors\":\"Wenhao Yang, Xiangtu Kong, Hui Yu, Xiaosu Feng, Haiwen Ni\",\"doi\":\"10.1177/20406207251359650\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>While carfilzomib has shown effectiveness in treating relapsed or refractory multiple myeloma (RRMM), the best frequency of dosing is still debated. This meta-analysis aims to investigate the differences in safety and effectiveness between once-weekly and twice-weekly carfilzomib treatment schedules for patients with RRMM.</p><p><strong>Methods: </strong>A thorough search of five databases was performed. We calculated pooled relative risks (RRs), hazard ratios (HRs), and 95% confidence intervals (95% CIs), and conducted heterogeneity and sensitivity analyses using StateMP 18 software.</p><p><strong>Results: </strong>Five studies met the inclusion criteria. Analysis indicated that once-weekly carfilzomib significantly enhanced progression-free survival (HR: 0.80, 95% CI: 0.69-0.94, <i>p</i> = 0.007). However, no statistical difference was observed in the pooled RRs for overall response rate (RR: 1.13, 95% CI: 0.94-1.38, <i>p</i> = 0.198) and complete response or better (RR: 2.08, 95% CI: 0.65-6.65, <i>p</i> = 0.217). The once-weekly regimen was notably associated with a reduction in adverse events (RR: 0.98, 95% CI: 0.96-1.00, <i>p</i> = 0.047) relative to the twice-weekly regimen.</p><p><strong>Conclusion: </strong>The results propose once-weekly carfilzomib as a viable alternative treatment option for RRMM.</p>\",\"PeriodicalId\":23048,\"journal\":{\"name\":\"Therapeutic Advances in Hematology\",\"volume\":\"16 \",\"pages\":\"20406207251359650\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-10-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501438/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20406207251359650\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406207251359650","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：虽然卡非佐米已显示出治疗复发或难治性多发性骨髓瘤（RRMM）的有效性，但最佳给药频率仍存在争议。本荟萃分析旨在调查每周一次和每周两次卡非佐米治疗方案对RRMM患者的安全性和有效性差异。方法：对5个数据库进行全面检索。我们计算了合并相对危险度（rr）、风险比（hr）和95%置信区间（95% ci），并使用StateMP 18软件进行了异质性和敏感性分析。结果：5项研究符合纳入标准。分析表明，每周一次的卡非佐米显著提高无进展生存期（HR: 0.80, 95% CI: 0.69-0.94, p = 0.007）。然而，总缓解率（RR: 1.13, 95% CI: 0.94-1.38, p = 0.198）和完全缓解或更好（RR: 2.08, 95% CI: 0.65-6.65, p = 0.217）的合并RRs无统计学差异。与每周两次的治疗方案相比，每周一次的治疗方案与不良事件的减少显著相关（RR: 0.98, 95% CI: 0.96-1.00, p = 0.047）。结论：研究结果表明，每周一次的卡非佐米是RRMM的可行替代治疗方案。
Comparative analysis of once-weekly versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma: a meta-analysis.
Background: While carfilzomib has shown effectiveness in treating relapsed or refractory multiple myeloma (RRMM), the best frequency of dosing is still debated. This meta-analysis aims to investigate the differences in safety and effectiveness between once-weekly and twice-weekly carfilzomib treatment schedules for patients with RRMM.
Methods: A thorough search of five databases was performed. We calculated pooled relative risks (RRs), hazard ratios (HRs), and 95% confidence intervals (95% CIs), and conducted heterogeneity and sensitivity analyses using StateMP 18 software.
Results: Five studies met the inclusion criteria. Analysis indicated that once-weekly carfilzomib significantly enhanced progression-free survival (HR: 0.80, 95% CI: 0.69-0.94, p = 0.007). However, no statistical difference was observed in the pooled RRs for overall response rate (RR: 1.13, 95% CI: 0.94-1.38, p = 0.198) and complete response or better (RR: 2.08, 95% CI: 0.65-6.65, p = 0.217). The once-weekly regimen was notably associated with a reduction in adverse events (RR: 0.98, 95% CI: 0.96-1.00, p = 0.047) relative to the twice-weekly regimen.
Conclusion: The results propose once-weekly carfilzomib as a viable alternative treatment option for RRMM.
期刊介绍：
Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology, providing a forum in print and online for publishing the highest quality articles in this area.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
